Sana Biotechnology (NASDAQ:SANA) versus Mosaic ImmunoEngineering (OTCMKTS:CPMV) Critical Analysis

Mosaic ImmunoEngineering (OTCMKTS:CPMV) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Institutional & Insider Ownership

88.2% of Sana Biotechnology shares are owned by institutional investors. 81.0% of Mosaic ImmunoEngineering shares are owned by insiders. Comparatively, 30.1% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Mosaic ImmunoEngineering and Sana Biotechnology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mosaic ImmunoEngineering	0	0	0	0	0.00
Sana Biotechnology	0	1	6	0	2.86

Sana Biotechnology has a consensus target price of $10.80, indicating a potential upside of 316.99%. Given Sana Biotechnology’s stronger consensus rating and higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Mosaic ImmunoEngineering.

Profitability

This table compares Mosaic ImmunoEngineering and Sana Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mosaic ImmunoEngineering	N/A	N/A	-1,371.05%
Sana Biotechnology	N/A	-84.22%	-44.97%

Volatility and Risk

Mosaic ImmunoEngineering has a beta of -0.13, suggesting that its share price is 113% less volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500.

Valuation and Earnings

This table compares Mosaic ImmunoEngineering and Sana Biotechnology”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mosaic ImmunoEngineering	N/A	N/A	-$1.01 million	($0.12)	-4.48
Sana Biotechnology	N/A	N/A	-$283.26 million	($0.88)	-2.94

Mosaic ImmunoEngineering is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Summary

Sana Biotechnology beats Mosaic ImmunoEngineering on 7 of the 11 factors compared between the two stocks.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.

About Sana Biotechnology

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company’s product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin’s lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.